Status:
COMPLETED
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Multiple Sclerosis, Relapsing-remitting
Eligibility:
All Genders
18-55 years
Brief Summary
The primary purpose of this study is to evaluate the overall safety and efficacy of Tecfidera (Dimethyl Fumarate) as an oral treatment for Korean participants with relapsing-remitting multiple scleros...
Eligibility Criteria
Inclusion
- The decision by the treating physician to prescribe Tecfidera is made before participating in the post marketing surveillance (PMS)
- A participant data release consent form is signed and dated by the participant and/or legal representative
- A Korean participant is diagnosed as relapsing-remitting MS per approved Korean label
Exclusion
- Participants with hypersensitivity to active ingredient or any of the excipients of Tecfidera according to the approved Korean label
- Participants with unresolved serious infection
- Participants who are participating in another study
Key Trial Info
Start Date :
June 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 14 2022
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT05366036
Start Date
June 14 2017
End Date
January 14 2022
Last Update
May 9 2022
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Site #20
Cheonan, Chungcheongnam-do, South Korea
2
Site #15
Ansan, Gyeonggi-do, South Korea
3
Site #08
Bucheon-si, Gyeonggi-do, South Korea
4
Site #09
Goyang-si, Gyeonggi-do, South Korea